N-n Or N=c(-n)-n Containing (e.g., Hydrazines, Hydrazones, Or Guanidines, Etc.) Patents (Class 514/565)
-
Publication number: 20130071439Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.Type: ApplicationFiled: January 10, 2011Publication date: March 21, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
-
Publication number: 20130064905Abstract: New fibroblast growth factor receptor 1 (FGFR1) inhibitors have been identified which are useful for promoting the retention and/or growth of keratin fibers, such as hair of the scalp, hair of the face (moustache, beard, etc.), eyebrows, eyelashes, and the like. The FGFR1 inhibitors may be formulated in effective amounts in a variety of cosmetic and personal care products.Type: ApplicationFiled: September 13, 2011Publication date: March 14, 2013Applicant: AVON PRODUCTS, INC.Inventors: Michele C. Duggan, Satish Parimoo, Cheng Hwang
-
Publication number: 20130059096Abstract: A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a D-amino acid, said composition being essentially free of the corresponding L-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the D-amino acid is selected from the group consisting of D-alanine, D-cysteine, D-aspartic acid, D-glutamic acid, D-histidine, D-isoleucine, D-lysine, D-leucine, D-asparagine, D-proline, D-glutamine, D-arginine, D-serine, D-threonine, D-valine, D-tryptophan, D-tyrosine, and a combination thereof.Type: ApplicationFiled: January 10, 2011Publication date: March 7, 2013Applicant: President and Fellows of Harvard CollegeInventors: Richard Losick, Jon Clardy, Roberto Kolter, Illana Kolodkin-Gal, Diego Romero, Shugeng Cao
-
Patent number: 8389578Abstract: The invention provides methods and compositions for treating or preventing neurological disorders.Type: GrantFiled: November 23, 2005Date of Patent: March 5, 2013Assignee: Adamas Pharmaceuticals, IncInventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8383626Abstract: There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided a method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.Type: GrantFiled: February 1, 2010Date of Patent: February 26, 2013Assignee: Henry Ford Health SystemInventors: Michael Chopp, Rui Lan Zhang
-
Publication number: 20130035381Abstract: The invention provides a virus-inactivating composition with pH of 3.8 to 5.5, containing (A) 0.02 to 0.3 M arginine and (B) a component such as 0.01 to 10 mM flavonoid, polyphenol, or ascorbic acid derivative, 0.005 to 5 mass % of an arginine derivative, and 0.1 to 2.5 mass % of an extract solution of natural product.Type: ApplicationFiled: August 22, 2012Publication date: February 7, 2013Inventors: Daisuke EJIMA, Haruna SATO, Hajime KOYAMA, Tsutomu ARAKAWA
-
Patent number: 8367730Abstract: The task of this invention is in use of composition containing natural metabolites—amino acids, and in method of its administration which make it possible to increase skin repigmentation through sulfurcontaining compounds rise and activation of endogenic metabolic reactions, and to get persistent normalization of melanogenesis thus improving skin integument and as a consequence patient's quality of life. Composition includes L cystine, L glutamic acid and glycine in the following quantity, mg: L cystine 85 ± 10%, L glutamic acid 85 ± 10%, Glycine 85 ± 10% The amino acid composition mentioned above must be administered 3 times a day for 5 weeks independent of meal in accordance with method of increase of skin integument repigmentation in vitiligo. The course can be repeated in 4-5 weeks.Type: GrantFiled: April 28, 2011Date of Patent: February 5, 2013Assignee: Nekimmercheskoe Uchrezhdenie “Nauchno-Issledovatel'skij Institut Ttsitokhimii I Molekulyarnoyj Farmakologii”Inventors: Irina Markovna Korsunskaya, Yaroslav Ryurikovich Nartsissov, Yaroslav Ryurikovich Nartsissov
-
Publication number: 20130023581Abstract: In order to reduce the amount of an organism attractant substance remaining inside concrete that tends be used wastefully and also to allow the organism attractant substance to effectively flow out gradually in a long period of time, an environmentally active, preserving and repairing-use concrete block is provided in which the air content and flowability of the concrete are increased, and the congregating and growing effects for fishes and shellfishes and the adhering and growing effects for algae are maintained so that a high attractant effect by odor of the organism attractant substance is obtained.Type: ApplicationFiled: October 19, 2010Publication date: January 24, 2013Applicants: AJINOMOTO CO., INC., Nikken Kogaku CO., LTDInventors: Takaki Yukimoto, Yasuhiro Kaneko, Seishi Tokunaga, Hirokazu Nishimura, Tatsuru Tabohashi, Masaki Kobayashi, Kazuhiro sato, Chizuru Tara
-
Patent number: 8354450Abstract: The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.Type: GrantFiled: October 21, 2010Date of Patent: January 15, 2013Assignees: Vireo Systems, Inc., Board of Regents of the University of NebraskaInventors: Donald W. Miller, Jonathan L. Vennerstrom, Mark C. Faulkner
-
Publication number: 20120329872Abstract: A new finished feed for domestic pets is proposed, containing at least one guanidinoacetic acid component as the active component with regard to nutritional physiology. The new finished feed which preferably has a water content of >8% by weight, can be produced in an extremely economical manner, wherein the main component has a significantly higher stability during passage through the gastrointestinal tract and is therefore only converted into creative under physiological conditions. For this reason the guanidinoacetic acid is also utilized to a high degree by the target group which is in particular cats and dogs.Type: ApplicationFiled: July 2, 2012Publication date: December 27, 2012Applicant: Alzchem Trostberg GmbHInventors: Thomas Gastner, Hans-Peter Krimmer
-
Patent number: 8333987Abstract: The present invention provides compositions and methods for identifying, monitoring, and/or treating tissue inflammation caused by diseases or injury. Inflammatory mediators from the Nourin family are provided as diagnostic markers to detect or monitor a disease or injury that results in inflammation. In addition, the Nourin family antagonist, Nourexin-4 is provided as a therapy to treat diseases or injury. Further, cyclocreatine is provided as an inhibitor of Nourin formation, which can be used as a therapy to treat injury and inflammation.Type: GrantFiled: September 30, 2009Date of Patent: December 18, 2012Inventors: Salwa Elgebaly, Elliott Schiffmann, Tamer Elbayoumi
-
Patent number: 8324280Abstract: Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (?-Methyl-dopahydrazine), MFMD (?-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-?-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer.Type: GrantFiled: August 7, 2009Date of Patent: December 4, 2012Assignee: The University of British ColumbiaInventors: Latif Wafa, Paul Rennie
-
Publication number: 20120301420Abstract: The present invention relates to hair treatment compositions and methods. More particularly, the invention relates to hair treatment compositions comprising lipids and creatine. The hair treatment compositions of the present invention may be used to improve the tensile properties of hair, such as hair elasticity and strength.Type: ApplicationFiled: August 10, 2012Publication date: November 29, 2012Inventors: Lane A. Duvel, Ernest H. Brumbaugh, Matthew D. Berg
-
Publication number: 20120302519Abstract: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates.Type: ApplicationFiled: February 3, 2011Publication date: November 29, 2012Applicant: MEH ASSOCIATES, INC.Inventor: Mark E. Hediger
-
Publication number: 20120282307Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8303979Abstract: The invention relates to products and methods for increasing the productivity in farming by improving the fertility of healthy farming mammals. More in particular, the invention relates to products and methods for improving the fertility of animals by reducing placental insufficiency. According to the invention, this is obtained by providing a product which is enriched in L-arginine. The arginine products of the invention may be applied to improve fertility, which may be used in improving the yield in viable offspring of an animal livestock.Type: GrantFiled: January 22, 2004Date of Patent: November 6, 2012Assignee: Nutreco Nederland B.V.Inventor: Tette van der Lende
-
Patent number: 8303995Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Methods of reducing triglycerides or reducing C-reactive protein levels are also provided.Type: GrantFiled: August 16, 2010Date of Patent: November 6, 2012Assignees: Board of Regents, The University of Texas System, Neogenis Laboratories, Inc.Inventors: Nathan Scott Bryan, Janet Zand
-
Publication number: 20120276152Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.Type: ApplicationFiled: February 6, 2012Publication date: November 1, 2012Inventors: Syed Hossainy, John Stankus, Mikael Trollsas, Dariush Davalian
-
Patent number: 8298589Abstract: Compositions comprising a nitrite salt, a nitrate salt, and ascorbic acid are provided in several embodiments. Use of said composition in a method of enhancing cardiovascular performance or treating adverse cardiovascular event in a mammal is also provided.Type: GrantFiled: June 15, 2009Date of Patent: October 30, 2012Assignee: Board of Regents, The University of Texas SystemInventor: Nathan Scott Bryan
-
Publication number: 20120263698Abstract: A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described.Type: ApplicationFiled: April 20, 2012Publication date: October 18, 2012Inventor: Elizabeth K. Barber
-
Publication number: 20120258087Abstract: The subject of the invention is an isotonic beverage with chelates containing carbohydrates, mineral amino acid chelates, L-carnitine, sweeteners, flavouring substances, and a diluent, the essential feature of the beverage being the content of up to 0.1 wt % of mineral components in the form of mineral amino acid chelates, preferably bisglycinates and glycinates, from 0.1 to 50 wt % of isomaltulose, up to 15 wt % of L-carnitine and/or its derivatives, from 5 to 84% of carbohydrates, up to 50 wt % of bioactive substances, up to 50 wt % of flavouring substances, up to 80 wt % of polyalcohols, diluents, tableting aids, stabilizers, antioxidants, dyes, and 0.013-25 wt % of sweeteners, whereby its osmolarity is 275-295 mOsm/kg and pH is 2-5.Type: ApplicationFiled: January 4, 2010Publication date: October 11, 2012Applicant: OLIMP LABORATORIES SP. Z O.O.Inventors: Marcin Jedlinski, Rafal Jedlinski, Piotr Kula, Justyna Widlak-Kargul, Gertruda Birus-Marszalek
-
Patent number: 8282952Abstract: The invention relates to insect attractants containing compounds with pentagonal heterocyclic structures that are effective in attracting fruitflies.Type: GrantFiled: March 11, 2008Date of Patent: October 9, 2012Assignee: Activetrad (Proprietary) LimitedInventor: Christoffel J. Smit
-
Publication number: 20120238629Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.Type: ApplicationFiled: March 21, 2012Publication date: September 20, 2012Inventors: Thomas GASTNER, Hans-Peter Krimmer
-
Publication number: 20120237567Abstract: Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed.Type: ApplicationFiled: March 20, 2012Publication date: September 20, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Jeroen Hagendoorn, Dai Fukumura, Timothy P. Padera, Rakesh K. Jain
-
Publication number: 20120231051Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.Type: ApplicationFiled: May 29, 2012Publication date: September 13, 2012Inventors: Yatendra Kumar GUPTA, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
-
Publication number: 20120225144Abstract: An extraction method for extracts of Geranium or Pelargonium with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Geranium or Pelargonium prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.Type: ApplicationFiled: March 2, 2011Publication date: September 6, 2012Applicant: Northern Innovations and Formulations Corp.Inventors: James Akrong, Shawn Shirazi, Vincent Scalisi, Jason Peters
-
Publication number: 20120190652Abstract: The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD in the pre-symptomatic phase of the disease or to distinguishing PD from another neurological disorder. The method of the invention comprises measuring the amount of soluble ?-synuclein oligomers in a cerebrospinal fluid sample taken from an individual. The method optionally also comprises measuring the total amount of ?-synuclein in the CSF sample, calculating the ratio of the amount of ?-synuclein oligomers to the total amount of ?-synuclein, and thereby determining whether or not the individual has PD. The method of the invention can be used in clinical trials to measure the effect of drugs in both PD animal models and human PD patients.Type: ApplicationFiled: September 13, 2010Publication date: July 26, 2012Applicant: United Arab Emirates UniversityInventor: Omar El-Agnaf
-
Publication number: 20120172450Abstract: A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.Type: ApplicationFiled: December 9, 2011Publication date: July 5, 2012Applicant: BROADY HEALTH SCIENCES, LLCInventor: Brunde Broady
-
Publication number: 20120157515Abstract: Disclosed herein Methods and composition for the treatment of an individual with “Burning Feet Syndrome”. Included are the manner and process of making the composition, administration, uses, and effective therapeutic amounts of Pantothenic acid and Alpha-lipoic acid with no adverse side effects. The composition can be used to prophylax (prevent), treat acute or chronic symptoms caused by “Burning Feet Syndrome”. In combination with certain adjuvants, carriers, vehicles and delivery systems to improve the efficacy.Type: ApplicationFiled: December 19, 2010Publication date: June 21, 2012Inventor: John Bowman White, III
-
Publication number: 20120141391Abstract: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.Type: ApplicationFiled: June 29, 2011Publication date: June 7, 2012Applicant: AVICENA GROUP, INC.Inventor: Rima Kaddurah-Daouk
-
Publication number: 20120142722Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. In another aspect of the invention there is provided a conjugate, comprising a cytotoxic agent and a modulating moiety, the modulating moiety serving to target apoptotic cells.Type: ApplicationFiled: June 23, 2010Publication date: June 7, 2012Inventors: Ilan Ziv, Anat Shirvan, Hagit Grimberg
-
Publication number: 20120141383Abstract: The invention relates to a preparation comprising a creatine component, which has excellent bio-availability and leads to improved creatine retention in the human and animal body. The present invention further relates to a method for the production of said preparation, and to the use thereof as a nutritional supplement, functional food, animal feed additive, pharmaceutical, and as an additive for cosmetic and dermatologic formulations.Type: ApplicationFiled: December 18, 2008Publication date: June 7, 2012Inventors: Thomas Gastner, Frauke Warrikoff, Barbara Nieß, Josef Fuest
-
Publication number: 20120135943Abstract: The invention relates to a dialysis solution for haemodialysis or peritoneal dialysis, said solution having a theoretical osmolarity within the range of from 250 to 550 mosm/L and a pH value within the range of from 4.9 to 8.0, said solution comprising a creatine compound and one or more electrolytes, wherein the concentration of the creatine compound is not more than 50 mM.Type: ApplicationFiled: July 21, 2010Publication date: May 31, 2012Applicant: CREARENE LTD.Inventors: Ulrich Kirschner, Jan Bulle
-
Patent number: 8188147Abstract: Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.Type: GrantFiled: May 16, 2008Date of Patent: May 29, 2012Assignee: Vanderbilt UniversityInventors: Marshall L. Summar, Brian W. Christman, Frederick E. Barr
-
Publication number: 20120128724Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: ApplicationFiled: November 22, 2011Publication date: May 24, 2012Applicant: The Regents of the University of Colorado, a body corporateInventors: M. Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Publication number: 20120122878Abstract: The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.Type: ApplicationFiled: June 30, 2008Publication date: May 17, 2012Inventors: Baltazar Gomez-Mancilla, Fabrizio Gasparini
-
Publication number: 20120108664Abstract: The present invention generally relates to the transdermal delivery of substances In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments.Type: ApplicationFiled: November 29, 2011Publication date: May 3, 2012Applicant: Strategic Science & Technologies, LLCInventor: Eric Thor Fossel
-
Publication number: 20120101069Abstract: The present invention relates to a haemodialysis solution or concentrate thereof comprising creatine compound(s) and the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof. Furthermore, the present invention is directed to a method for preparing creatine-containing dialysis solutions and concentrates. In addition, the present invention is directed to a method for treating patients with dialysis dependent renal failure with creatine compounds and to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of the patients organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells (specifically including blood cells) of these patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities.Type: ApplicationFiled: March 10, 2010Publication date: April 26, 2012Applicant: CREARENE LTD.Inventors: Michael Moeddel, Theo Wallimann
-
Publication number: 20120093893Abstract: A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.Type: ApplicationFiled: December 22, 2011Publication date: April 19, 2012Inventors: David A. Edwards, Richard P. Batycky, Lloyd Johnston
-
Publication number: 20120077876Abstract: This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R1 and R2 are hydrogen, alkyl, or aryl radicals.Type: ApplicationFiled: January 8, 2010Publication date: March 29, 2012Applicant: Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. KGInventors: Bernd Clement, Dennis Schade
-
Publication number: 20120065261Abstract: The present invention relates to the use of creatine compounds, such as, for example, creatine monohydrate, creatine pyruvate and creatine ascorbate, for the treatment of skin.Type: ApplicationFiled: April 13, 2011Publication date: March 15, 2012Applicant: Avicena Group, Inc.Inventors: Belinda Tsao Nivaggioli, Bolko Zu Stolberg, Maisie Wong-Paredes
-
Publication number: 20120065266Abstract: The present invention provides an oral composition which can more effectively prevent or improve functional gastrointestinal disorders, particularly upper gastrointestinal dysfunction, specifically functional dyspepsia, and is highly safe and suitable for long-term ingestion. The oral composition of the present invention contains sodium glutamate and arginine hydrochloride at a molar ratio of 1:1. The aforementioned composition can be provided as an agent for the prophylaxis or improvement of functional gastrointestinal disorder, and can also be provided in a food or drink.Type: ApplicationFiled: September 13, 2011Publication date: March 15, 2012Applicants: NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, AJINOMOTO CO. INCInventors: Shinichi Fujita, Yoshiaki Hanzawa, Noriko Yasa, Hiroyuki Matsueda, Hideaki Kihara, Motoyasu Kusano, Osamu Kawamura, Yasuyuki Shimoyama, Hiroko Hosaka, Hiroaki Zai, Atsuto Nagoshi
-
Publication number: 20120058123Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: October 12, 2011Publication date: March 8, 2012Applicant: PANMIRA PHARMACEUTICALS, LLC.Inventors: John Howard HUTCHINSON, Brian Andrew Stearns, Jill Melissa Scott, Yen Pham Truong, Jeffrey Roger Roppe, Nicholas Simon Stock, Jeannie M. Arruda, Thomas Jon Seiders, Bowei Wang, Deborah Volkots
-
Patent number: 8101569Abstract: The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.Type: GrantFiled: July 2, 2010Date of Patent: January 24, 2012Assignee: Northern Innovations and Formulations, Inc.Inventors: Jason Peters, Michele Molino
-
Publication number: 20120014934Abstract: A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.Type: ApplicationFiled: July 13, 2011Publication date: January 19, 2012Inventors: Paul Altaffer, Jeffrey M. Wuagneux, Pi-Yu Hsu
-
Publication number: 20120010291Abstract: Disclosed are creatine ?-alaninate, compositions and formulations containing same, and methods of use therefor.Type: ApplicationFiled: August 12, 2009Publication date: January 12, 2012Inventor: Bruce W. Kneller
-
Publication number: 20120003158Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.Type: ApplicationFiled: April 8, 2011Publication date: January 5, 2012Inventors: Danny ALEXANDER, Jeffrey SHUSTER, Joshua KORZENIK, Garrett ZELLA
-
Publication number: 20120004284Abstract: The invention relates to methods of treating or preventing acquired or congenital mitochondrial diseases or disorders, including treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for treating such disorders or diseases.Type: ApplicationFiled: September 1, 2009Publication date: January 5, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATIONInventors: David A. Ostrov, Peter Stacpoole, Arun Srivastava
-
Publication number: 20110313012Abstract: A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine.Type: ApplicationFiled: November 15, 2010Publication date: December 22, 2011Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Patent number: RE43711Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.Type: GrantFiled: October 17, 2011Date of Patent: October 2, 2012Assignee: Civitas Therapeutics, Inc.Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich